The BTN sleep and recovery protocol prioritizes sleep architecture optimization and growth hormone pulse amplitude over waking anabolic interventions. The core thesis: 9+ hours of consolidated sleep with maximized slow-wave and REM percentages produces greater net anabolism than abbreviated sleep plus additional training volume. The protocol uses three primary levers—ibutamoren (MK-677) at 25 mg nightly for GH secretagogue activity, gamma-hydroxybutyrate or its analogs at 2–3 g for GABA-B agonism and sleep consolidation, and selective MAO inhibition for REM rebound. Bloodwork at week 4 typically shows IGF-1 elevation of 40–60% above baseline, prolactin transient elevation in the first 90 minutes post-dose, and fasting glucose increase of 8–12 mg/dL. This is not polyphasic experimentation or marginal sleep hygiene adjustment—this is pharmacologically enforced deep recovery to create a 16-hour anabolic window nightly.
Mechanism
The BTN sleep protocol manipulates three intersecting pathways: growth hormone secretion via ghrelin receptor agonism, sleep consolidation through GABA-B receptor activation, and REM latency reduction via monoamine oxidase inhibition.
Ibutamoren (MK-677) is a non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone release from anterior pituitary somatotrophs. It bypasses somatostatin-mediated negative feedback by acting upstream at the hypothalamic arcuate nucleus. Single-dose studies show GH area-under-curve increases of 60–130% with corresponding IGF-1 elevation that peaks at 14–21 days of continuous dosing. Unlike exogenous GH administration, MK-677 preserves physiologic pulsatility—critical because continuous elevation causes receptor downregulation. The 24-hour half-life allows once-nightly dosing timed to endogenous nocturnal GH pulse, amplifying rather than replacing endogenous secretion.
Gamma-hydroxybutyrate (GHB) or its prodrug gamma-butyrolactone (GBL) acts as a GABA-B receptor agonist and weak GHB receptor agonist. At the 2–3 g range, it produces rapid sleep onset (15–25 minutes), consolidation of slow-wave sleep in the first 3–4 hours, and a characteristic rebound into extended REM in hours 5–8. Unlike GABAergic sedatives (benzodiazepines, Z-drugs), GHB does not suppress slow-wave architecture—it enhances it. The result is measurably deeper sleep with greater delta-wave percentage and reduced sleep fragmentation. Tolerance develops to sedative effects within 10–14 days at static dosing, requiring dose escalation or cycling.
Selegiline at 2.5–5 mg or other MAO-B inhibitors reduce catabolism of dopamine and phenethylamine, which indirectly modulates REM latency and sleep pressure. The mechanism is indirect: MAO-B inhibition increases waking dopaminergic tone, which sharpens the contrast between wake and sleep states, resulting in faster sleep onset and more consolidated REM periods. The effect is subtle compared to the other two agents but becomes significant in multi-week protocols where cumulative sleep debt is reduced.
Protocol
The full BTN sleep protocol runs in 8-week blocks with a 2-week washout. Compounds are dosed 60–90 minutes before target sleep time in a dark, cool environment (18–20°C ambient temperature).
Week 1–8 stack:
- MK-677: 25 mg orally, taken with the final meal of the day or 30 minutes before GHB dose. Start at 12.5 mg for the first 3 nights if insulin sensitivity is a concern or fasting glucose is above 95 mg/dL. Timing is critical—dosing at sleep onset maximizes overlap with endogenous nocturnal GH pulse (typically 1–2 hours post-sleep-onset).
- GHB or GBL: 2 g initial dose, escalate by 0.5 g every 5–7 days if sleep latency exceeds 20 minutes or if early waking occurs. Maximum effective dose is typically 3.5 g; above this, respiratory depression risk increases without further sleep benefit. GBL converts to GHB via lactonase at roughly 1:1.3 ratio—if using GBL, start at 1.5 g and titrate similarly. Redosing mid-sleep is common (1–1.5 g at hour 4) to prevent early waking, but increases dependency risk.
- Selegiline: 2.5 mg sublingually upon waking, or 5 mg oral if using the conventional tablet form. MAO-B selectivity is lost above 10 mg daily, increasing tyramine sensitivity and hypertensive risk—stay below this threshold.
Cycle structure: 8 weeks on, 2 weeks off. During the washout, substitute L-theanine 400 mg, magnesium glycinate 600 mg, and glycine 3 g as a non-receptor-active sleep stack. This prevents rebound insomnia and allows GH receptor resensitization.
Stacking considerations: If running a testosterone base above 300 mg weekly, reduce MK-677 to 12.5 mg nightly—combined anabolic signaling plus elevated fasting glucose can push HbA1c into prediabetic range (5.7–6.4%). If using trenbolone, the protocol is largely ineffective due to tren-induced sleep fragmentation and night sweats overriding GABAergic consolidation. If stacking with CJC-1295/ipamorelin, discontinue MK-677—redundant GH pathway activation without additive benefit.
Training adjustment: Shift high-CNS-demand sessions (heavy compounds, max-effort sets) to mid-morning (10 AM–12 PM) when dopaminergic tone from selegiline peaks. Avoid training within 4 hours of sleep onset—cortisol and catecholamine elevation will delay GHB-mediated sleep onset.
Monitoring
Bloodwork at weeks 0, 4, and 8, drawn fasting at 8 AM (12+ hours post-MK-677 dose to capture trough IGF-1):
- IGF-1: Target 300–400 ng/mL. Below 300 suggests poor response (check compliance, consider dose increase to 37.5 mg). Above 450 increases acromegaly-adjacent risks (carpal tunnel, insulin resistance).
- Fasting glucose and HbA1c: Expect glucose increase of 8–12 mg/dL within 2 weeks. HbA1c should remain below 5.7%. If glucose exceeds 105 mg/dL or HbA1c crosses 5.7%, add metformin 500 mg with the final meal of the day or reduce MK-677 to 12.5 mg.
- Prolactin: Transient elevation is expected (up to 30 ng/mL) within 90 minutes of MK-677 dosing but should normalize by morning. Sustained elevation above 20 ng/mL at trough indicates either overdosing or individual hypersensitivity—reduce to 12.5 mg or introduce cabergoline at 0.25 mg twice weekly.
- Cortisol (morning and evening): Morning cortisol should remain 10–20 µg/dL; evening below 5 µg/dL. Flattened diurnal rhythm (high evening cortisol) suggests incomplete recovery despite the protocol—assess training volume and psychological stress.
- Complete blood count: Watch RBC, hemoglobin, and hematocrit if stacking with erythropoietic compounds. Sleep apnea (a contraindication for GHB) often coexists with polycythemia.
Subjective markers: Sleep latency below 20 minutes, zero mid-sleep waking, waking without alarm after 8.5–9.5 hours, absence of daytime somnolence. If daytime somnolence persists beyond week 2, suspect apnea or GHB overdose—reduce dose by 0.5 g.
Wearable data (Oura, WHOOP) can confirm protocol efficacy: slow-wave sleep should comprise 20–25% of total sleep time (up from typical 15–18%), REM 23–28% (up from 20–23%). If wearables show no architecture change by week 3, GHB dose is likely subtherapeutic.
Risks and Mitigation
GHB respiratory depression and dependence: Doses above 4 g or combination with alcohol or other CNS depressants significantly increase respiratory depression risk. Dependence develops rapidly with nightly use beyond 12 weeks—withdrawal includes rebound insomnia, tremor, and in severe cases, seizure. Mitigation: never exceed 3.5 g, never redose more than once nightly, and always run the 2-week washout. If planning to extend beyond 8 weeks, taper by 0.5 g weekly rather than stopping abruptly.
Insulin resistance and hyperglycemia: MK-677 increases fasting glucose and insulin demand via direct hypothalamic signaling and indirect IGF-1-mediated effects. Mitigation: metformin 500–1000 mg nightly, berberine 500 mg twice daily, or add fasted morning cardio (30–45 minutes, zone 2). If HbA1c exceeds 5.7%, discontinue MK-677.
Water retention and carpal tunnel: Elevated GH and IGF-1 cause sodium retention and extracellular fluid expansion. Mitigation: reduce sodium intake below 3 g daily, consider low-dose diuretic (hydrochlorothiazide 12.5 mg every other day), and monitor for nocturnal hand numbness (early carpal tunnel). If carpal tunnel symptoms develop, reduce MK-677 dose or discontinue.
Prolactin-mediated libido suppression: Transient prolactin spikes are common but sustained elevation causes anhedonia and erectile dysfunction. Mitigation: cabergoline 0.25 mg twice weekly if trough prolactin exceeds 20 ng/mL.
Selegiline hypertensive crisis: At doses above 10 mg daily, MAO-B selectivity is lost, creating risk of tyramine-mediated hypertensive events. Mitigation: stay at or below 5 mg daily, avoid aged cheeses, cured meats, and fermented foods.
Comparisons
BTN sleep protocol vs exogenous GH monotherapy: Exogenous GH at 2–4 IU nightly produces similar IGF-1 elevation but suppresses endogenous pulsatility, increases cost 10-fold, and requires daily subcutaneous injection. The BTN protocol preserves pulsatile secretion, costs under $150 monthly for all compounds, and is orally bioavailable. However, exogenous GH offers dose titration precision and zero impact on glucose in non-predisposed individuals. For pure sleep architecture improvement without GH augmentation, exogenous GH is inferior—it does not consolidate slow-wave sleep.
GHB vs GABAergic sedatives (zolpidem, eszopiclone, benzodiazepines): Z-drugs and benzodiazepines reliably induce sleep but suppress slow-wave architecture and REM, negating recovery benefit. GHB enhances slow-wave sleep in the first half of the night and produces REM rebound in the second half. However, GHB has significant dependence liability and legal scheduling (Schedule I in the US, Schedule III as sodium oxybate for narcolepsy). GBL is unscheduled in some jurisdictions but metabolically identical. For individuals unable to source GHB/GBL, the protocol loses 60% of its efficacy.
MK-677 vs CJC-1295/ipamorelin: Peptide secretagogues require twice-daily subcutaneous injection, have shorter half-lives, and cost more. MK-677 offers once-nightly oral dosing and sustained IGF-1 elevation. Peptides allow more precise pulsatility control and avoid the glucose impact of MK-677. For a sleep-focused protocol, MK-677 is superior due to timing simplicity and nocturnal GH pulse amplification.
Common Mistakes
Underdosing GHB and expecting results: 1 g of GHB will not consolidate sleep—it produces mild sedation without architecture change. Effective doses start at 2 g. Individuals accustomed to recreational GHB dosing (5–7 g) must recognize that the therapeutic window for sleep is 2–3.5 g; above this, the sedation is so profound that natural sleep cycles are overridden, and morning grogginess becomes disabling.
Dosing MK-677 in the morning: Timing MK-677 to amplify the nocturnal GH pulse is critical. Morning dosing produces a midday GH spike that does not align with sleep-mediated anabolism and increases daytime hunger and lethargy. Always dose 60–90 minutes before bed.
Ignoring glucose monitoring: Hyperglycemia is the most common reason to discontinue the protocol, and it is entirely preventable with early detection and metformin introduction. Waiting until symptoms (polyuria, polydipsia) manifest means HbA1c is already in prediabetic range.
Training too close to sleep onset: High-intensity training within 4 hours of GHB dosing delays sleep onset and reduces slow-wave percentage. The CNS must downregulate before GABAergic agents can consolidate sleep. Schedule last training session no later than 6 PM if target sleep time is 10 PM.
Running the protocol without a washout: Continuous GHB use beyond 12 weeks guarantees dependence. Continuous MK-677 beyond 12 weeks risks receptor desensitization and progressive insulin resistance. The 2-week washout is not optional—it is the difference between a sustainable protocol and a liability.
Bottom Line
- The BTN sleep protocol delivers 9+ hours of consolidated, architecture-optimized sleep using MK-677 25 mg, GHB 2–3 g, and selegiline 2.5–5 mg nightly in 8-week blocks.
- Expect IGF-1 elevation of 40–60%, fasting glucose increase of 8–12 mg/dL, and measurably deeper slow-wave and REM sleep within 2 weeks.
- Monitor fasting glucose, HbA1c, IGF-1, and prolactin at weeks 0, 4, and 8—add metformin if glucose exceeds 105 mg/dL or HbA1c crosses 5.7%.
- Never exceed 3.5 g GHB, always run the 2-week washout, and avoid training within 4 hours of dosing.
- This is not a sleep hygiene intervention—this is forced anabolic recovery via pharmacologic sleep consolidation and GH pulse amplification.